SAN DIEGO and TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

In addition to the clinical posters at SAWC Fall 2024, the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight Booth #431 in the Exhibition Hall.

PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTX) (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT ...

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced a poster ...

Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics (AKBA) ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

Positive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin clinical development with Phase 1 single and ...

Lorenza Mattia is a postdoc based at Sapienza University in Rome and she won the 2024 ECTS-Amgen Clinical Poster Forum Award ECTS-Amgen Clinical Poster Forum Award Lorenza Mattia is a postdoc based at ...